The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C07 | Beta blocking agents | |
| 3 | C07A | Beta blocking agents | |
| 4 | C07AA | Beta blocking agents, non-selective | |
| 5 | C07AA07 | Sotalol |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.16 g |
| PAREN - Parenteral | 0.16 g |
| Active Ingredient | Description | |
|---|---|---|
| Sotalol |
D,l-sotalol is a non-selective hydrophilic β-adrenergic receptor blocking agent, devoid of intrinsic sympathomimetic activity or membrane stabilizing activity. Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SOTACOR Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| SOTALOL Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
